Singh S P, Han L, Murali R, Solis L, Roth J, Ji L, Wistuba I, Kundra V
Department of Experimental Diagnostic Imaging, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Hum Gene Ther. 2011 Jan;22(1):55-64. doi: 10.1089/hum.2010.109. Epub 2010 Dec 6.
The most common cause of cancer-related deaths in North America is lung cancer, 85% of which is non-small cell lung cancer (NSCLC). Gene therapy is a promising approach, but has been hindered by lack of methods for localizing and quantifying gene expression in vivo. Human somatostatin receptor subtype-2 (SSTR2)-based reporters can be used to follow gene expression in vivo using ligands with greater affinity for this subtype. NSCLCs can express SSTR subtypes, which may interfere with SSTR2-based reporters. We assessed whether a SSTR2-based reporter can serve as a reporter of gene transfer into NSCLCs. SSTR subtype expression was assessed in NSCLC cell lines A549, H460, and H1299 using RT-PCR. After infection with an adenovirus containing hemagglutinin-A-tagged-SSTR2 (Ad-HA-SSTR2) or control insert, expression was assessed by immunologic techniques and binding to clinically-approved (111)In-octreotide. In vivo, after magnetic resonance (MR) imaging, intrathoracic H460 tumors were injected with Ad-HA-SSTR2 or control virus (n = 6 mice/group) under ultrasound guidance. Intravenous injection of (111)In-octreotide 2 days later was followed by planar and single-photon emission computed tomography (SPECT) imaging. Biodistribution into tumors was assessed in vivo using anatomic MR and functional gamma-camera images and ex vivo using excised organs/tumors. In human lung tumor samples (n = 70), SSTR2 expression was assessed using immunohistochemistry. All three NSCLC cell lines expressed different SSTR subtypes, but none expressed SSTR2. Upon Ad-HA-SSTR2 infection, HA-SSTR2 expression was seen in all three cell lines using antibodies targeting the HA domain or (111)In-octreotide targeting the receptor domain (p < 0.05). Intrathoracic tumors infected with Ad-HA-SSTR2 were clearly visible by gamma-camera imaging; expression was quantified by both in vivo and ex vivo biodistribution analysis and demonstrated greater uptake in tumors infected with Ad-HA-SSTR2 compared with control virus (p < 0.05). Immunohistochemistry found that 78% of NSCLCs are negative for and 13% have low levels of SSTR2 expression. It is concluded that SSTR2-based reporters can serve as reporters of gene transfer into NSCLCs.
在北美,与癌症相关的死亡最常见的原因是肺癌,其中85%是非小细胞肺癌(NSCLC)。基因治疗是一种很有前景的方法,但一直受到缺乏体内基因表达定位和定量方法的阻碍。基于人类生长抑素受体2型(SSTR2)的报告基因可用于利用对该亚型具有更高亲和力的配体来追踪体内基因表达。NSCLC可表达SSTR亚型,这可能会干扰基于SSTR2的报告基因。我们评估了基于SSTR2的报告基因是否可作为基因导入NSCLC的报告基因。使用逆转录聚合酶链反应(RT-PCR)在NSCLC细胞系A549、H460和H1299中评估SSTR亚型表达。在用含有血凝素-A-标签-SSTR2(Ad-HA-SSTR2)或对照插入片段的腺病毒感染后,通过免疫技术和与临床批准的铟-111奥曲肽结合来评估表达。在体内,磁共振(MR)成像后,在超声引导下向胸腔内的H460肿瘤注射Ad-HA-SSTR2或对照病毒(每组n = 6只小鼠)。2天后静脉注射铟-111奥曲肽,随后进行平面和单光子发射计算机断层扫描(SPECT)成像。使用解剖学MR和功能性γ相机图像在体内评估肿瘤的生物分布,并使用切除的器官/肿瘤在体外进行评估。在人肺肿瘤样本(n = 70)中,使用免疫组织化学评估SSTR2表达。所有三种NSCLC细胞系均表达不同的SSTR亚型,但均不表达SSTR2。在用Ad-HA-SSTR2感染后,使用靶向HA结构域的抗体或靶向受体结构域的铟-111奥曲肽在所有三种细胞系中均可见HA-SSTR2表达(p < 0.05)。通过γ相机成像可清晰看到感染Ad-HA-SSTR2的胸腔内肿瘤;通过体内和体外生物分布分析对表达进行定量,结果表明与对照病毒相比,感染Ad-HA-SSTR2的肿瘤摄取更多(p < 0.05)。免疫组织化学发现,78%的NSCLC对SSTR2表达呈阴性,13%的表达水平较低。结论是基于SSTR2的报告基因可作为基因导入NSCLC的报告基因。